Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2010-018794-38-IT
EUCTR2010-018794-38-IT
Active, not recruiting
Not Applicable

EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTP

FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO0 sitesJuly 26, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTHROMBOTIC THROMBOCYTOPENIC PURPURAMedDRA version: 9.1Level: LLTClassification code 10037562
DrugsMABTHERA

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
THROMBOTIC THROMBOCYTOPENIC PURPURA
Sponsor
FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
Status
Active, not recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 26, 2010
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO

Eligibility Criteria

Inclusion Criteria

  • •\-DIAGNOSIS OF ACQUIRED AUTOIMMUNE RECURRENT TTP
  • •\-AGE \>18 YEARS
  • •\-CLINICAL REMISSION AT THE TIME OF ENROLMENT
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\-PREGNANCY
  • •\-ONGOING INFECTION
  • •\-SEVERE CARDIAC DISEASE
  • •\-HISTORY OF HYPERSENSITIVITY TO RITUXIMAB

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating Polyneuropathy
JPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE Trial
JPRN-jRCT2041180037Iijima Masahiro25
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.
EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Active, not recruiting
Phase 1
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVAS
EUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108
Active, not recruiting
Not Applicable
Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR.Efficacy of rituximab in patients with Rheumatoid Arthritis, by measurement of disease parameters through magnetic resonance of the hand. RESONAR study.Pacientes con artritis reumatoide (AR) activa refractarios a uno o más fármacos antiTNF (definido por un DAS28>3,2).MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2008-002381-55-ESROCHE FARMA, S.A.